NDC 71872-7294-01 - Naloxone Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 71872-7294
- Requested NDC
- 71872-7294-01
- Package NDCs from labels
- 71872-7294-1, 71872-7294-01
- Manufacturer
- Medical Purchasing Solutions, LLC
- Effective date
- 2023-04-24
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Naloxone Hydrochloride - Medical Purchasing Solutions, LLC | Medical Purchasing Solutions, LLC | 2023-04-24 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71872-7294-1 | Naloxone Hydrochloride | 2 mL in 1 SYRINGE | INJECTION | 2 | 3 | |
| 71872-7294-1 | Naloxone Hydrochloride | 1 in 1 BAG | INJECTION | 1 | 3 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 71872-7294 | NALOXONE HYDROCHLORIDE INJECTION [MEDICAL PURCHASING SOLUTIONS, LLC] | 3 | Current NDC, Legacy NDC, 2 package rows | 20230425_ea4ea2fe-af48-0b3c-e053-2a95a90a0ad5.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | REMEDYREPACK INC. | 68df290c-d776-4cfc-9565-332eb56c4723 | 2026-02-10 | Warnings, Adverse reactions | ANDA072076 1191250 F850569PQR |
| naloxone hydrochloride | NALOXONE HYDROCHLORIDE | Lifestar Pharma LLC | aef6719c-cd71-46ee-b7b1-1806b939bf3e | 2026-02-09 | Warnings, Adverse reactions | F850569PQR |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Camber Pharmaceuticals, Inc. | 221195e4-de08-414c-af08-a611a74789de | 2026-01-30 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | AvKARE | 1766a7f1-d301-945f-e063-6294a90ac6f4 | 2026-01-14 | Warnings | F850569PQR |
| RiVive | NALOXONE HYDROCHLORIDE | Harm Reduction Therapeutics, Inc. | 1c4f1b9d-1c70-4666-a90e-2f5d2c670d4d | 2026-01-13 | Warnings | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Sina Health Inc | 2879294f-9af9-459e-e063-6394a90a0820 | 2026-01-12 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Padagis Israel Pharmaceuticals Ltd | b5d40220-f194-4835-b70c-f304ecb222d5 | 2026-01-06 | Warnings | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Dr. Reddy's Laboratories, Inc. | b1303f15-c48b-a44d-b28a-72f370094e02 | 2026-01-01 | Warnings, Adverse reactions | 1191250 F850569PQR |
| Zubsolv | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | Orexo US, Inc. | 5f5cfcfe-d52b-49e6-8fe4-550477332dd2 | 2025-12-27 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | BPI Labs LLC | 5de44ee7-6525-4857-9a67-8882e96dbeb5 | 2025-12-26 | Warnings, Adverse reactions | 1191250 F850569PQR |
| Suboxone | BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE | INDIVIOR INC. | 8a5edcf9-828c-4f97-b671-268ab13a8ecd | 2025-12-22 | Warnings, Adverse reactions | F850569PQR |
| Narcan | NALOXONE HYDROCHLORIDE | Emergent Devices Inc. | 724df050-5332-4d0a-9a5f-17bf08a547e1 | 2025-12-05 | Warnings, Adverse reactions | F850569PQR |
| ZIMHI | NALOXONE HYDROCHLORIDE | ZMI Pharma Inc. | 523c0909-bff6-4010-988a-53de18b7cb3f | 2025-12-04 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Strategic Sourcing Services LLC | 577fbd57-7054-4536-86c1-d43bc99cc7b1 | 2025-11-19 | Warnings | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Henry Schein, Inc. | ddeebc32-9aab-4a2f-8c87-74335d17d5ef | 2025-10-28 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | ProPharma Distribution | 3f2bb95a-aeca-c0b7-e063-6394a90a627b | 2025-09-19 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | e6467385-6990-498c-8a0e-f4a40ef33cb7 | 2025-09-02 | Warnings, Adverse reactions | 1191250 F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | AMERISOURCE BERGEN | cce38c13-0d2f-49bb-94fa-6f2bbb4d5984 | 2025-08-31 | Warnings | F850569PQR |
| PENTAZOCINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | PENTAZOCINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | Lupin Pharmaceuticals,Inc. | 017ef042-40aa-44c9-baa8-037f06356845 | 2025-08-28 | Boxed warning, Warnings, Adverse reactions | F850569PQR |
| KLOXXADO | NALOXONE HCL | Hikma Specialty USA Inc. | ebf0f833-c1c0-487c-8f29-01fa8c61b6cb | 2025-08-25 | Warnings, Adverse reactions | F850569PQR |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.